<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126659</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02920</org_study_id>
    <secondary_id>NCI-2012-02920</secondary_id>
    <secondary_id>CDR0000438709</secondary_id>
    <secondary_id>2004-0516</secondary_id>
    <secondary_id>6630</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <nct_id>NCT00126659</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
      growth and by blocking blood flow to the tumor. Giving sorafenib before and after surgery may
      be an effective treatment for kidney cancer. This phase II trial is studying how well
      sorafenib works in treating patients who are undergoing surgery for metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Efficacy of BAY 43-9006 (sorafenib tosylate) by evaluating response rate. II. Toxicities
      of BAY 43-9006 in metastatic renal cell carcinoma (RCC). III. Intraoperative and
      peri/postoperative safety of BAY 43-9006.

      SECONDARY OBJECTIVES:

      I. Time to progression. II. Duration of response. II. Overall Survival.

      TERTIARY OBJECTIVES:

      I. Tissue expression of VEGFR-2/phospho-VEGFR-2, PDGFR/phospho-PDGFR, FGFR/phospho-FGFR,
      ERK/phospho-ERK, RAF-1/phospho-RAF-1, p38/phospho-p38, Akt/phospho-Akt, P27, Ki67, TGF-alpha,
      and TUNEL pre- and post- therapy (optional studies).

      II. Oligonucleotide analysis of tissue pre- and post-therapy (optional studies).

      OUTLINE: This is a non-randomized study. Patients are sequentially assigned to 1 of 3
      treatment groups.

      GROUP I: Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral
      sorafenib twice daily on days 15-84.

      GROUP II: Patients receive oral sorafenib twice daily on days 1-7. Patients undergo
      cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days
      22-84.

      GROUP III: Patients receive oral sorafenib twice daily on days 1-28. Patients undergo
      cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days
      43-84.

      In all groups, patients with stable or regressing disease continue to receive oral sorafenib
      twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity.
      Some patients may continue treatment for longer than 1 year at the discretion of the
      investigator.

      After completion of study treatment, patients are followed every 2 months.

      PROJECTED ACCRUAL: A total of 45 patients (15 per treatment group) will be accrued for this
      study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of BAY 43-9006 by Evaluating Response Rate</measure>
    <time_frame>Every 2 weeks during 4 week cycle</time_frame>
    <description>Response rate (participants with response/total number participants) where number of participants with response evaluated using international criteria proposed by (RECIST) Committee of: Complete Response: Disappearance all target lesions; Partial Response (PR): &gt; 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD. Progressive Disease (PD): &gt; 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease:
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Following 10 weeks of treatment or until disease progression</time_frame>
    <description>Time, in weeks, after treatment until disease progresses. Repeat radiologic studies to evaluate disease progression or response after 10 weeks of BAY 43 9006 therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response</measure>
    <time_frame>Following 10 weeks of treatment, followed every 2 weeks or until disease progression</time_frame>
    <description>Duration of overall response is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started), measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of participants surviving from baseline (treatment) to death due to any cause measured in days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Group I (cytoreductive nephrectomy and sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.
In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.
In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.
In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo cytoreductive nephrectomy</description>
    <arm_group_label>Group I (cytoreductive nephrectomy and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Group II (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <arm_group_label>Group III (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group I (cytoreductive nephrectomy and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Group II (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <arm_group_label>Group III (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (cytoreductive nephrectomy and sorafenib tosylate)</arm_group_label>
    <arm_group_label>Group II (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
    <arm_group_label>Group III (sorafenib tosylate and cytoreductive nephrectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed metastatic clear cell RCC who
             are eligible for cytoreductive nephrectomy as agreed upon by Medical Oncology and
             Urology team members; patients with metastatic disease eligible for cytoreductive
             nephrectomy should have the following characteristics: resectable primary tumor (no
             gross adjacent organ invasion, no or minimal abdominal lymphadenopathy, no or minimal
             inferior vena caval involvement), bulk of metastatic disease within the primary tumor,
             absence of multiple liver metastases, no more than 2 organ sites involved with
             metastases

          -  Patients must have measurable disease, defined as a lesion that can be accurately
             measured in at least one dimension (longest diameter to be recorded) and measures &gt;=
             20 mm with conventional techniques or &gt;= 10 mm with spiral computed tomography (CT)
             scan

          -  ECOG performance status =&lt; 1

          -  Absolute neutrophil count &gt;= 1,500/uL

          -  Platelets &gt;= 100,000/uL

          -  Hgb &gt; 9.0 g/dL

          -  Total bilirubin =&lt; 2.0 mg/dl

          -  Albumin &gt; 3.0 g/dL

          -  Serum creatinine =&lt; 2.0 mg/dl

          -  AST (SGOT) and/or ALT (SGPT) =&lt; 2.5 x institutional upper limit of normal for subjects
             without evidence of liver metastases

          -  AST (SGOT) and/or ALT (SGPT) =&lt; 5 X institutional upper limit of normal for subjects
             with documented liver metastases

          -  Female patients of childbearing potential must have a normal plasma beta human
             chorionic gonadotropin (beta-HCG) within 24 hours prior to enrolling in the study due
             to the possible teratogenic effect; however, patients will be eligible if their
             beta-HCG is elevated and is determined to be due to malignancy

          -  Patients of child fathering or childbearing potential must agree to practice a form of
             medically acceptable birth control while on study

          -  Patients must give written informed consent prior to initiation of therapy, in keeping
             with the policies of the institution; patients with a history of major psychiatric
             illness must be judged able to fully understand the investigational nature of the
             study and the risks associated with the therapy

          -  Patients must have ability to comply with study and/or follow-up procedures

          -  Prior biopsy material (blocks or unstained slides) must be available for comparison
             purposes

        Exclusion Criteria:

          -  No prior malignancy is allowed, except for non-melanoma skin cancer, in situ carcinoma
             of any site, or other cancers for which the patient has been adequately treated and
             disease free for 5 years

          -  Patients must not have received any systemic anticancer therapy or radiotherapy within
             4 weeks prior to entering the study or those who have not recovered from adverse
             events due to agents administered more than 4 weeks earlier

          -  Patients must not be scheduled to receive another experimental drug while on this
             study; patients are permitted to be on concomitant bisphosphonates

          -  Patients who are incapable of swallowing pills are excluded from this study

          -  Patients must not have a primary brain tumor, any brain metastases, leptomeningeal
             disease, seizure disorders not controlled with standard medical therapy, or history of
             stroke

          -  Patients must not have active acute infections that could be worsened by anticancer
             therapy or interfere with this study

          -  Patients must not have clinically significant cardiovascular disease, recent
             myocardial infarction (i.e. last 6 months), (unstable angina), New York Heart
             Association (NYHA) grade II or greater congestive heart failure, serious cardiac
             dysrhythmia requiring medication, or peripheral vascular disease (grade II or greater)

          -  Patients must not have history of other diseases, metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             might affect the interpretation of the results of the study or render the subject at
             high risk from treatment complications

          -  Patients with uncontrolled hypertension &gt; 140/90 are excluded from the study

          -  Patients must not have any history of bleeding diathesis; patients must not be on
             therapeutic anticoagulation; prophylactic anticoagulation (i.e. low dose coumadin) of
             venous or arterial access devices is allowed provided that the requirements for PT,
             INR or PTT are met

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with BAY 43-9006

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Jonasch</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <results_first_submitted>September 28, 2012</results_first_submitted>
  <results_first_submitted_qc>November 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2012</results_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 11, 2006 to July 12, 2007. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>This trial was run at the same time as a competing trial and suffered from poor accrual. For that reason it was closed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cytoreductive Nephrectomy Day 0</title>
          <description>Group 1: Immediate cytoreductive nephrectomy, two weeks rest, and 10 weeks Sorafenib 400 mg orally mouth twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib + Cytoreductive Nephrectomy Day 8</title>
          <description>Group 2: One week Sorafenib 400 mg orally mouth twice a day, cytoreductive nephrectomy, two weeks rest, 9 weeks Sorafenib</description>
        </group>
        <group group_id="P3">
          <title>Sorafenib + Cytoreductive Nephrectomy Day 29</title>
          <description>Group 3: Four weeks Sorafenib 400 mg orally mouth twice a day, Cytoreductive Nephrectomy, two weeks rest, 6 weeks Sorafenib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytoreductive Nephrectomy Day 0</title>
          <description>Group 1: Immediate cytoreductive nephrectomy, two weeks rest, and 10 weeks Sorafenib 400 mg orally mouth twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib + Cytoreductive Nephrectomy Day 8</title>
          <description>Group 2: One week Sorafenib 400 mg orally mouth twice a day, cytoreductive nephrectomy, two weeks rest, 9 weeks Sorafenib</description>
        </group>
        <group group_id="B3">
          <title>Sorafenib + Cytoreductive Nephrectomy Day 29</title>
          <description>Group 3: Four weeks Sorafenib 400 mg orally mouth twice a day, Cytoreductive Nephrectomy, two weeks rest, 6 weeks Sorafenib</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of BAY 43-9006 by Evaluating Response Rate</title>
        <description>Response rate (participants with response/total number participants) where number of participants with response evaluated using international criteria proposed by (RECIST) Committee of: Complete Response: Disappearance all target lesions; Partial Response (PR): &gt; 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD. Progressive Disease (PD): &gt; 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease:
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started.</description>
        <time_frame>Every 2 weeks during 4 week cycle</time_frame>
        <population>Unable to assess response due to small sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Cytoreductive Nephrectomy Day 0</title>
            <description>Group 1: Immediate cytoreductive nephrectomy, two weeks rest, and 10 weeks Sorafenib 400 mg orally mouth twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib + Cytoreductive Nephrectomy Day 8</title>
            <description>Group 2: One week Sorafenib 400 mg orally mouth twice a day, cytoreductive nephrectomy, two weeks rest, 9 weeks Sorafenib</description>
          </group>
          <group group_id="O3">
            <title>Sorafenib + Cytoreductive Nephrectomy Day 29</title>
            <description>Group 3: Four weeks Sorafenib 400 mg orally mouth twice a day, Cytoreductive Nephrectomy, two weeks rest, 6 weeks Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of BAY 43-9006 by Evaluating Response Rate</title>
          <description>Response rate (participants with response/total number participants) where number of participants with response evaluated using international criteria proposed by (RECIST) Committee of: Complete Response: Disappearance all target lesions; Partial Response (PR): &gt; 30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD. Progressive Disease (PD): &gt; 20% increase in sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease:
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started.</description>
          <population>Unable to assess response due to small sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time, in weeks, after treatment until disease progresses. Repeat radiologic studies to evaluate disease progression or response after 10 weeks of BAY 43 9006 therapy.</description>
        <time_frame>Following 10 weeks of treatment or until disease progression</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Response</title>
        <description>Duration of overall response is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started), measured in days.</description>
        <time_frame>Following 10 weeks of treatment, followed every 2 weeks or until disease progression</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The number of participants surviving from baseline (treatment) to death due to any cause measured in days.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib + Cytoreductive Nephrectomy</title>
          <description>All participants received Sorafenib 400 mg orally mouth twice a day for a total of 10 weeks over the course of the study and had surgical procedure Cytoreductive Nephrectomy before treatment with Sorafenib or in between courses of Sorafenib</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>neutrophils (ANC)</sub_title>
                <description>ANC = Absolute Neutrophil Count</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>watery eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>edema:head and neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection (other),</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>pain (chest/thorax)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain (joint)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Jonasch, MD / Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>caperez@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

